Clinical Pharmacokinetics of Meloxicam
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 36 (2), 115-126
- https://doi.org/10.2165/00003088-199936020-00003
Abstract
Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclooxygenase-2. Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of meloxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies. Neither moderate renal nor hepatic insufficiency significantly alter the pharmacokinetics of meloxicam. Dosage adjustment is not required in the elderly. Drug-drug interaction studies are available for some commonly co-prescribed medications. Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for this NSAID.Keywords
This publication has 31 references indexed in Scilit:
- Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugsInflammation Research, 1998
- Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX- inhibiting Therapies (SELECT) trial in osteoarthritisRheumatology, 1998
- Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogsJournal of Small Animal Practice, 1998
- Gastrointestinal tolerability of meloxicam and piroxicam: a double‐blind placebo‐controlled studyBritish Journal of Clinical Pharmacology, 1998
- Central antinociceptive effects of meloxicam on rat spinal cord in vitroNeuroReport, 1998
- An Open Study to Assess the Safety and Tolerability of Meloxicam 15 mg in Subjects with Rheumatic Disease and Mild Renal ImpairmentRheumatology, 1996
- Pharmacokinetics and tolerability of meloxicam after i.m. administrationBritish Journal of Clinical Pharmacology, 1996
- Interaction of Meloxicam with Cimetidine, Maalox, or AspirinThe Journal of Clinical Pharmacology, 1996
- Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteersEuropean Journal of Clinical Pharmacology, 1995
- Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity.1993